Vanda Pharmaceuticals' (VNDA) MAA for Fanaptum in Schizophrenia Accepted for Evaluation by EMA

December 22, 2015 4:33 PM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that its Marketing Authorization Application (MAA) for oral Fanaptum® tablets has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of schizophrenia in adults.

"The MAA validation demonstrates Vanda's commitment to offer another option to the healthcare community to treat a severe, disabling mental disorder," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO. "This continues our efforts to expand the availability of iloperidone to people who we believe would benefit from this treatment option."

The MAA is primarily supported by data from two placebo- and active-controlled clinical trials and one long term randomized clinical trial. Fanaptum® was shown to be superior to placebo in controlling symptoms of schizophrenia.

Iloperidone is currently approved in the U.S. as Fanapt® for the treatment of schizophrenia in adults. Fanapt® is also approved and marketed in Israel and Mexico.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Management Comments